56964-37-5

Basic information

• Product Name: (8E,24E)-5,6,17,19-tetrahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,9,11-trioxo-8-{[(4-prop-2-yn-1-ylpiperazin-1-yl)amino]methylidene}-1,2,8,9-tetrahydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate
• CAS NO: 56964-37-5
• Molecular Formula: C₄₅H₅₈N₄O₁₂
• Molecular Weight: 846.9616
• Mol File: 56964-37-5.mol
• Article Data: 4

Chemical Properties

• Density: 1.35g/cm³
• Refractive Index: 1.633
• CAS DataBase Reference: (8E,24E)-5,6,17,19-tetrahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,9,11-trioxo-8-{[(4-prop-2-yn-1-ylpiperazin-1-yl)amino]methylidene}-1,2,8,9-tetrahydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate(CAS DataBase Reference)
• NIST Chemistry Reference: (8E,24E)-5,6,17,19-tetrahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,9,11-trioxo-8-{[(4-prop-2-yn-1-ylpiperazin-1-yl)amino]methylidene}-1,2,8,9-tetrahydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate(56964-37-5)
• EPA Substance Registry System: (8E,24E)-5,6,17,19-tetrahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,9,11-trioxo-8-{[(4-prop-2-yn-1-ylpiperazin-1-yl)amino]methylidene}-1,2,8,9-tetrahydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate(56964-37-5)

Safety Data

• Hazardous Substances Data: 56964-37-5(Hazardous Substances Data)

Usage

General Description

"(8E,24E)-5,6,17,19-tetrahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,9,11-trioxo-8-{[(4-prop-2-yn-1-ylpiperazin-1-yl)amino]methylidene}-1,2,8,9-tetrahydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate" is a complex chemical compound with a long and detailed structure. It contains multiple functional groups such as hydroxy, methoxy, acetate, piperazin-1-ylamino, and imino, as well as a naphthofuran core. The compound's structure suggests potential biological activity and pharmaceutical relevance, possibly as a natural product or a synthetic analog with potential medicinal properties. Further research and analysis would be needed to fully understand its chemical and biological properties.

Upstream product

• 13292-22-3 C₃₈H₄₇NO₁₃ 
• 56964-23-9 1-amino-4-propargylpiperazine 
• 61429-04-7 1-nitroso-4-propargylpiperazine 
• 13292-22-3 3-formylrifamycin SV 

Relevant articles and documents

Semisynthetic Analogs of the Antibiotic Fidaxomicin - Design, Synthesis, and Biological Evaluation

The glycoslated macrocyclic antibiotic fidaxomicin (1, tiacumicin B, lipiarmycin A3) displays good to excellent activity against Gram-positive bacteria and was approved for the treatment of Clostridium difficile infections (CDI). Among the main limitations for this compound, its low water solubility impacts further clinical uses. We report on the synthesis of new fidaxomicin derivatives based on structural design and utilizing an operationally simple one-step protecting group-free preparative approach from the natural product. An increase in solubility of up to 25-fold with largely retained activity was observed. Furthermore, hybrid antibiotics were prepared that show improved antibiotic activities.

Synthesis of Tridecaptin-Antibiotic Conjugates with in Vivo Activity against Gram-Negative Bacteria

A series of tridecaptin-antibiotic conjugates were synthesized and evaluated for in vitro and in vivo activity against Gram-negative bacteria. Covalently linking unacylated tridecaptin A1 (H-TriA1) to rifampicin, vancomycin, and erythromycin enhanced their activity in vitro but not by the same magnitude as coadministration of the peptide and these antibiotics. The antimicrobial activities of the conjugates were retained in vivo, with the H-TriA1-erythromycin conjugate proving a more effective treatment of Klebseilla pneumoniae infections in mice than erythromycin alone or in combination with H-TriA1.